Search
-
A World of Research: 2019 in review
Looking back at what Ipsos research and analysis has told us about the world in the past year.
-
Flair Brazil 2020 - Watercolour or Mosaic
Flair goes to Brazil for the fifth time and finds a country grappling with a series of crises and changing consumer behaviour.
-
The Ipsos Almanac 2019
Welcome to the Ipsos 2019 Almanac - a look at what our research has told us about the state of Britain in another year of Brexit and a general election.
-
Sharpening physician insights: Integrating patient record auditing for increased accuracy and specificity [Webinar recording]
Listen to our webinar, co-hosted with Intellus Worldwide, and learn how you can leverage patient record auditing to develop a tailored portfolio strategy that helps physicians address their most challenging patient populations.
-
NATO is seen as a force for good, but support is low in key member states
Ipsos / King's College London multi-country poll on public attitudes and favourability towards NATO and its objectives.
-
Trend Obs 2020 - Welcome to the worrying twenties
Trend Obs is an international observatory for emerging dynamics that compiles ongoing changes in lifestyles and consumption around the world. Each year, Ipsos surveys trend setters* in several countries and this year’s countries are Brazil, the United States, France, the UK, Italy and China. The observatory provides brands with keys to understanding the society of the future and helps them to position themselves better within that society.
-
Ipsos Update - December 2019
This month’s edition of Ipsos Update features the latest research and thinking from Ipsos around the world on the future of mobility, world affairs, survey sampling and global infrastructure.
-
Global Infrastructure Index - Public satisfaction and priorities 2019
Majority across 28 countries are globally satisfied with national infrastructure.
-
Attitudes to and awareness of lung cancer for the Lung Ambition Alliance
New survey conducted for the Lung Ambition Alliance, in association with AstraZeneca, found that the majority of people (59%) are confident that in 5 years’ time a significantly higher proportion of those diagnosed with lung cancer will be cured compared to now.